Sunny Pharmtech Valuation

Is 6676 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6676 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6676's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6676's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6676?

Key metric: As 6676 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6676. This is calculated by dividing 6676's market cap by their current revenue.
What is 6676's PS Ratio?
PS Ratio	6.7x
Sales	NT$485.01m
Market Cap	NT$3.25b

6676 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.1x
Enterprise Value/EBITDA	69.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6676's PS Ratio compare to its peers?

The above table shows the PS ratio for 6676 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
4747 Johnson Chemical Pharmaceutical Works	5.1x	n/a	NT$3.1b
8279 Syngen BiotechLtd	1.8x	n/a	NT$3.6b
1777 SYN-TECH Chem. & Pharm	3.6x	n/a	NT$4.3b
8432 TSH Biopharm	2.3x	n/a	NT$2.4b
6676 Sunny Pharmtech	6.7x	n/a	NT$3.3b

Price-To-Sales vs Peers: 6676 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (3.2x).

Price to Sales Ratio vs Industry

How does 6676's PS Ratio compare vs other companies in the TW Pharmaceuticals Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
3705 YungShin Global Holding	1.9x	n/a	US$458.51m
1720 Standard Chemical & Pharmaceutical	1.7x	n/a	US$348.94m
4746 Formosa Laboratories	2x	7.8%	US$278.96m
3716 Cenra	0.6x	n/a	US$171.35m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6676 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the TW Pharmaceuticals industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is 6676's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6676 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6676's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

TSH Biopharm

NT$2.4b

Develops and markets pharmaceutical products in Taiwan and Asia.

8432

NT$63.30

-0.9%

24.6%

Winston Medical Supply

NT$1.6b

Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.

6817

NT$89.10

1.5%

-16.3%

RBC Bioscience

NT$247.2m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.05

-4.5%

18.7%